49
Participants
Start Date
September 30, 2004
Primary Completion Date
June 30, 2009
Study Completion Date
November 30, 2010
graft versus host disease prophylaxis/therapy
Within 72 hours after the initiation of medical therapy (e.g., corticosteroids, cyclosporine) for graft-vs-host disease, patients undergo donor MSC infusion over 10-15 minutes.
fluorescence in situ hybridization
Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.
immunoenzyme technique
Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.
immunohistochemistry staining method
Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.
laboratory biomarker analysis
Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.
in vitro-treated bone marrow transplantation
Within 72 hours after the initiation of medical therapy (e.g., corticosteroids, cyclosporine) for graft-vs-host disease, patients undergo donor MSC infusion over 10-15 minutes.
management of therapy complications
Patients will be evaluated for clinical signs and symptoms of GVHD weekly for up to 28 days.
Geauga Regional Hospital, Cleveland
Lake/University Ireland Cancer Center, Cleveland
University Suburban Health Center, Cleveland
UHHS Chagrin Highlands Medical Center, Cleveland
Southwest General Health Center, Cleveland
UHHS Westlake Medical Center, Cleveland
Mercy Cancer Center at Mercy Medical Center, Cleveland
Ireland Cancer Center at University Hosptials Case Medical Center, Case Comprehensive Cancer Center, Cleveland
National Cancer Institute (NCI)
NIH
Case Comprehensive Cancer Center
OTHER